Home
Veloxis

Veloxis Market Share Analysis for November 2025

Veloxis aims to create a community within the transplant space. Discover our partner affiliations and podcast episodes, and find us on social media to connect along your entire transplant journey.

Health > Biotechnology and Pharmaceuticals

Domainveloxis.com

Year Founded2002

Employees51 - 200

Annual Revenue$25M - $50M

Veloxis

Veloxis (including company regionals)

veloxis.com

See more website traffic and engagement information

Veloxis Revenue up to November 2025 is 25M - 50M

revenue generated by Veloxis top domains

Veloxis top domains revenue over 3 years

Revenue for Veloxis top domains

veloxis.com25M - 50M

See more with Sales Intelligence

Total visits to Veloxis's top domains

Understand Veloxis market share and potential market reach.

Total visits last 3 months

Subsidiaries Breakdown

veloxis.com3.6K

See more with Sales Intelligence

Avg. visit duration in Veloxis's top domains

Analyze Veloxis engagement metrics.

Average visit duration last 3 months

Subsidiaries Breakdown

veloxis.com00:00:29

See more with Sales Intelligence

Avg. pageviews on Veloxis's top domains

See how Veloxis keep users engaged, nurture their interest, and encourage them to take the next step.

Average page views last 3 months

Subsidiaries Breakdown

veloxis.com1.90

See more with Sales Intelligence

Veloxis top competitors by domain

Top similar sites in November 2025, ranked by their affinity

evaluategroup.comCompany NameEvaluate Ltd.Employees51 - 200HQUnited Kingdom, LondonAnnual revenue$75M - $100MTotal visits739Health > Biotechnology and Pharmaceuticals

Top technologies used by Veloxis

These are the website technologies, by industry, used by Veloxis top domains

Payment & Currencies (9)

Cart Functionality

Email Services (4)

Microsoft Exchange Online

Marketing (3)

Google Marketing Platform

Widget (3)

Twemoji

More Technologies

10

See all

News & Signals from Veloxis

With Similarweb Sales signals alerts, you’ll receive daily updates of recognized buying signals whenever new opportunities or threats arise in your target audience.

NewsVeloxis Pharmaceuticals, Inc. attends event World Transplant Congress.Veloxis Pharmaceuticals, Inc. (Veloxis), an Asahi Kasei company and a global specialty pharmaceutical company, is pleased to announce it will present new preclinical data at the upcoming World Transplant Congress (WTC) on pegrizeprument (also known as VEL-101), a novel subcutaneous CD28 co-stimulation blocker being developed as maintenance immunosuppression in kidney transplantation.

NewsVeloxis Pharmaceuticals, Inc. attended event 2024 American Transplant Congress on May 30th '24.CARY, N.C., U.S.A. (May 30, 2024) - Veloxis Pharmaceuticals, Inc. (Veloxis), a fully integrated specialty pharmaceutical company, is pleased to announce the presentation of VEL-101 research at the 2024 American Transplant Congress (ATC).

NewsAsahi Kasei Group acquired Veloxis Pharmaceuticals, Inc. for $1.6B on Jan 1st '20.In 2020, Asahi Kasei Corporation has acquired Veloxis Pharmaceuticals Inc.